NCT06178588 2026-02-24
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
University of Kansas Medical Center
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT05430698 2026-02-09
PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06739252 2026-01-28
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Peking University
Phase 2 Terminated
NCT05024513 2025-12-18
Biliary Drainage Plus HAIC in Locally Advanced pCCA
Peking University
Phase 2 Completed
NCT07030140 2025-06-22
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT06717464 2024-12-05
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Active not recruiting
NCT03003065 2023-08-22
PDT
Chinese University of Hong Kong
Phase 2 Completed
NCT04211168 2023-03-29
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Peking Union Medical College Hospital
Phase 2 Unknown